Compare KRKR & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRKR | GTBP |
|---|---|---|
| Founded | 2010 | 1965 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 8.5M |
| IPO Year | 2019 | N/A |
| Metric | KRKR | GTBP |
|---|---|---|
| Price | $4.25 | $0.67 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.1K | ★ 2.0M |
| Earning Date | 09-26-2025 | 02-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,966,526.00 | N/A |
| Revenue This Year | $182.55 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.11 | $0.54 |
| 52 Week High | $21.36 | $3.85 |
| Indicator | KRKR | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 42.87 | 42.16 |
| Support Level | $3.99 | $0.76 |
| Resistance Level | $4.78 | $0.87 |
| Average True Range (ATR) | 0.38 | 0.07 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 40.72 | 2.58 |
36KR Holdings Inc is a holding company and conducts its business mainly through its subsidiaries, a VIE, and subsidiaries of the VIE. The Group is engaging in providing content and business services to new economy participants in the PRC. Its content production process includes content creation, content editing, screening and monitoring, and content distribution. The Group mainly generates revenues from providing online advertising services, enterprise value-added services, and subscription services. The Group's principal operations and geographic markets are substantially located in PRC.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.